Adaptimmune Therapeutics PLC is UK based biopharmaceutical company focused on novel cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor T-cell platform. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. The company engineers TCRs to increase their affinity to cancer-specific peptides in order to destroy cancer cells in patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.